Skip to main content

Advertisement

Log in

Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis

  • Case Report
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy. The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure. After discontinuing the oral alendronate, the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis. Urinary volume and serum creatinine levels recovered to the normal range, with urinary protein disappearing completely within 40 days. This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Roger MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88(Suppl 12):2961–78.

    Article  Google Scholar 

  2. Lioté F, Boval-Boizard B, Fritz P, Kuntz D. Lymphocyte subsets in pamidronate-induced lymphopenia. Br J Rheumatol. 1995;34:993–5.

    Article  PubMed  Google Scholar 

  3. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17:897–907.

    Article  CAS  PubMed  Google Scholar 

  4. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12:1164–72.

    PubMed  CAS  Google Scholar 

  5. Stratton JD, Warwicker P. Relapse of nephrotic syndrome triggered by bisphosphonates. Nephrol Dial Transplant. 2002;17:1856–7.

    Article  PubMed  Google Scholar 

  6. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment. The fracture intervention trial long-term extension (FLEX): A randomized trial. JAMA. 2006;296:2927–38.

    Article  CAS  PubMed  Google Scholar 

  7. de Nijs RNJ, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006;355:675–84.

    Article  PubMed  Google Scholar 

  8. Dijkman H, Smeets B, van der Laak J, Steenbergen E, Wetzels J. The parietal epithelial cell is crucially involved in human idiopathic focal segmental glomerulosclerosis. Kidney Int. 2005;68:1562–72.

    Article  PubMed  Google Scholar 

  9. Asano T, Niimura F, Pastan I, Fogo AB, Ichikawa I, Matsusaka T. Permanent genetic tagging of podocytes: Fate of injured podocytes in a mouse model of glomerular sclerosis. J Am Soc Nephrol. 2005;16:2257–62.

    Article  CAS  PubMed  Google Scholar 

  10. Marshall CB, Shankland SJ. Cell cycle and glomerular disease: A minireview. Nephron Exp Nephrol. 2006;102:e39–48.

    Article  PubMed  Google Scholar 

  11. Pascual J, Torrealba J, Myers J, Tome S, Samaniego M, Musat A, et al. Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate. Osteoporos Int. 2007;18:1435–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by a grant (to H.I.) from the Progressive Renal Diseases Research Project of the Ministry of Health, Labour and Welfare of Japan.

Conflict of interest statement

None declared.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hirokazu Imai.

About this article

Cite this article

Miura, N., Mizuno, N., Aoyama, R. et al. Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis. Clin Exp Nephrol 13, 85–88 (2009). https://doi.org/10.1007/s10157-008-0078-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-008-0078-x

Keywords

Navigation